Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.57 |
| ▸ | JAK3 | P52333 | 6/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | ITK | Q08881 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | TEC | P42680 | 1/20 | 0.48 |
| ▸ | TXK | P42681 | 1/20 | 0.48 |
| ▸ | BMX | P51813 | 1/20 | 0.48 |
| ▸ | CD69 | Q07108 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145128 | 0.92 | FGFR2 (0.61) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18002338 | 0.91 | JAK3 (0.63) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001204 | 0.90 | FGFR1 (0.65) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001549 | 0.90 | FGFR2 (0.63) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001867 | 0.89 | FGFR2 (0.55) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001674 | 0.89 | FGFR1 (0.65) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001040 | 0.89 | BTK (0.58) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001888 | 0.88 | FGFR2 (0.54) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL18001738 | 0.88 | BTK (0.58) | BTKJAK3FGFR2FGFR1KDR | |
| SCHEMBL16514050 | 0.87 | FGFR2 (0.68) | BTKJAK3FGFR2FGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | claimed |
| EP-3270694-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2018-01-24 | — | — | EP | claimed |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | claimed |
| WO-2016133935-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2016-08-25 | — | — | WO | claimed |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10947201-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | BTK 172/4885JAK3 110/4885FGFR2 365/4885 |
| US-10947201-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | BTK 172/4885JAK3 110/4885FGFR2 365/4885 |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | BTK 172/4885JAK3 110/4885FGFR2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.